Socioeconomic disparities and the genomic landscape of gastric cancer DOI Creative Commons

Daniel Zanabria,

Marco Gálvez-Niño, Jhajaira M. Araujo

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 2, 2024

Abstract The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration the possibility that different may be exposed to risk factors. We conducted a prospective pilot study two cities (Lima and Ica). This enrolled 15 low status (LSES) medium/high (MHSES). profiling samples was done through FoundationOne CDx platform. compared need for targeted therapy immunotherapy between LSES MHSES. genes higher rates alterations TP53 (73.3% vs. 50.0%, P = 0.2635); CDH1 (26.7% 28.6%, 1); CDKN2A (20.0% KRAS (33.3% 7.1%, 0.1686); ARID1A 14.3%, MLL2 (13.3% 21.4%, 1) SOX9 0.0%, 0.0421) versus HMSES, respectively. There no significant difference tumor mutational burden ( 0.377) or microsatellite 1). group had according gene involvement alterations. A exists among status, which result immunotherapy.

Language: Английский

Socioeconomic disparities and the genomic landscape of gastric cancer DOI Creative Commons

Daniel Zanabria,

Marco Gálvez-Niño, Jhajaira M. Araujo

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 2, 2024

Abstract The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration the possibility that different may be exposed to risk factors. We conducted a prospective pilot study two cities (Lima and Ica). This enrolled 15 low status (LSES) medium/high (MHSES). profiling samples was done through FoundationOne CDx platform. compared need for targeted therapy immunotherapy between LSES MHSES. genes higher rates alterations TP53 (73.3% vs. 50.0%, P = 0.2635); CDH1 (26.7% 28.6%, 1); CDKN2A (20.0% KRAS (33.3% 7.1%, 0.1686); ARID1A 14.3%, MLL2 (13.3% 21.4%, 1) SOX9 0.0%, 0.0421) versus HMSES, respectively. There no significant difference tumor mutational burden ( 0.377) or microsatellite 1). group had according gene involvement alterations. A exists among status, which result immunotherapy.

Language: Английский

Citations

3